Jiangsu Yuyue Medical Equipment & Supply (002223) investor relations material

Executive summary

• Revenue for H1 2026 was ¥4.57 billion, down 1.92% year-over-year; net profit attributable to shareholders was ¥842.81 million, down 29.92% year-over-year.

• Operating cash flow increased 1.31% year-over-year to ¥1.18 billion.

• The company maintained a strong focus on R&D, investing ¥306 million (6.7% of revenue).

• Overseas revenue grew 35.76% year-over-year, reaching ¥824 million.

• Proposed interim dividend: ¥4 per 10 shares, totaling approximately ¥398 million.

Financial highlights

• Gross margin was 49.80%, down 0.56 percentage points year-over-year.

• Total assets at period-end were ¥16.90 billion, up 5.08% from year-end 2025.

• Net assets attributable to shareholders were ¥13.33 billion, up 0.69% from year-end 2025.

• Basic and diluted EPS were both ¥0.8443, down 29.93% year-over-year.

• Adjusted net profit (excluding share-based payments) was ¥849.87 million, down 29.75% year-over-year.

Outlook and guidance

• The company will continue to focus on high-value, high-margin medical devices and expand in global markets.

• Strategic priorities include digitalization, wearable health, and global expansion.

• R&D and product innovation remain core to future growth.